WO1998058965A3 - B7-binding molecules for treating immune diseases - Google Patents
B7-binding molecules for treating immune diseases Download PDFInfo
- Publication number
- WO1998058965A3 WO1998058965A3 PCT/EP1998/003791 EP9803791W WO9858965A3 WO 1998058965 A3 WO1998058965 A3 WO 1998058965A3 EP 9803791 W EP9803791 W EP 9803791W WO 9858965 A3 WO9858965 A3 WO 9858965A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecules
- antigen
- binding molecules
- immune diseases
- cross
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98939523A EP0988321A2 (en) | 1997-06-20 | 1998-06-22 | B7-binding molecules for treating immune diseases |
AU88005/98A AU8800598A (en) | 1997-06-20 | 1998-06-22 | B7-binding molecules for treating immune diseases |
CA002292415A CA2292415A1 (en) | 1997-06-20 | 1998-06-22 | B7-binding molecules for treating immune diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97870092.0 | 1997-06-20 | ||
EP97870092 | 1997-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998058965A2 WO1998058965A2 (en) | 1998-12-30 |
WO1998058965A3 true WO1998058965A3 (en) | 1999-05-14 |
Family
ID=8231013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/003791 WO1998058965A2 (en) | 1997-06-20 | 1998-06-22 | B7-binding molecules for treating immune diseases |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0988321A2 (en) |
AU (1) | AU8800598A (en) |
CA (1) | CA2292415A1 (en) |
WO (1) | WO1998058965A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001068133A1 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
WO2001068132A1 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of a combination of agents that modulate b7 activity in inhibiting intestinal allograft rejection |
WO2001068134A2 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Therapies that improve graft survival, using antibodies against a b7 antigen |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
US6965018B2 (en) | 2000-06-06 | 2005-11-15 | Bristol-Myers Squibb Company | Antibodies directed to B7-related polypeptide, BSL-2 |
US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
US20040236088A1 (en) * | 2001-08-02 | 2004-11-25 | Heuer Josef Georg | Novel polypeptide analogs and fusions and their methods of use |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EA012622B1 (en) | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Bispecific fusion antibodies with enhanced serum half-life |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
CN101724071A (en) | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | Single domain antibodies against TNFRl and methods of use therefor |
NZ555464A (en) | 2004-12-02 | 2010-03-26 | Domantis Ltd | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
GB0621513D0 (en) | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
WO2010009391A1 (en) | 2008-07-18 | 2010-01-21 | Bristol-Myers Squibb Company | Compositions monovalent for cd28 binding and methods of use |
MX338825B (en) | 2008-10-02 | 2016-05-03 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins. |
WO2014120916A1 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
IL254335B2 (en) * | 2015-03-16 | 2023-04-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Isolated peptides derived from the b7 ligand dimer interface and uses thereof |
JP6936221B2 (en) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス, インコーポレイテッド | CD80 extracellular domain polypeptides and their use in cancer treatment |
EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
CN110305220B (en) * | 2018-03-27 | 2022-10-11 | 孙嘉琳 | Cancer-targeted enhanced anti-tumor fusion protein and preparation method and application thereof |
CN110305221B (en) * | 2018-03-27 | 2022-10-11 | 孙嘉琳 | Enhanced anti-tumor fusion protein, preparation method and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995022619A1 (en) * | 1994-02-18 | 1995-08-24 | Chiron Corporation | B7-1-specific ligands, and their use for the induction of t cell anergy |
WO1996014865A1 (en) * | 1994-11-10 | 1996-05-23 | Repligen Corporation | Methods for inhibiting graft versus host disease in bone marrow transplantation |
WO1996040878A1 (en) * | 1995-06-07 | 1996-12-19 | Idec Pharmaceuticals Corporation | Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions |
WO1998003670A1 (en) * | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
-
1998
- 1998-06-22 WO PCT/EP1998/003791 patent/WO1998058965A2/en not_active Application Discontinuation
- 1998-06-22 CA CA002292415A patent/CA2292415A1/en not_active Abandoned
- 1998-06-22 EP EP98939523A patent/EP0988321A2/en not_active Withdrawn
- 1998-06-22 AU AU88005/98A patent/AU8800598A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995022619A1 (en) * | 1994-02-18 | 1995-08-24 | Chiron Corporation | B7-1-specific ligands, and their use for the induction of t cell anergy |
WO1996014865A1 (en) * | 1994-11-10 | 1996-05-23 | Repligen Corporation | Methods for inhibiting graft versus host disease in bone marrow transplantation |
WO1996040878A1 (en) * | 1995-06-07 | 1996-12-19 | Idec Pharmaceuticals Corporation | Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions |
WO1998003670A1 (en) * | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
Non-Patent Citations (3)
Title |
---|
P. ILIADES ET AL.: "Triabodies: single chain Fv fragments without a linker form trivalent trimers.", FEBS LETTERS, vol. 409, no. 3, 16 June 1997 (1997-06-16), AMSTERDAM, NL, pages 437 - 441, XP002047810 * |
P. PERRIN ET AL.: "Distinct requirements of lymph node T cells for B7-1 (CD80) and B7-2 (CD86) costimulation in response to concanavalin A.", THE FASEB JOURNAL, vol. 10, no. 6, 30 April 1996 (1996-04-30), BETHESDA, MD, USA, pages A1454, XP002047809 * |
P. PERRIN ET AL.: "Mitogenic stimulation of T cells reveals differing contributions for B7-1 (CD80) and B7-2 (CD86) costimulation.", IMMUNOLOGY, vol. 90, no. 4, April 1997 (1997-04-01), OXFORD, GB, pages 534 - 542, XP002047808 * |
Also Published As
Publication number | Publication date |
---|---|
AU8800598A (en) | 1999-01-04 |
EP0988321A2 (en) | 2000-03-29 |
CA2292415A1 (en) | 1998-12-30 |
WO1998058965A2 (en) | 1998-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998058965A3 (en) | B7-binding molecules for treating immune diseases | |
DK0752869T3 (en) | Cells with numerous altered epitopes on a surface antigen for use in transplantation | |
NO986173L (en) | Procedure for activating dendritic cells | |
ATE403680T1 (en) | PRODUCTION OF TETRAVALENT ANTIBODIES | |
CA2290485A1 (en) | Method for the production of non-immunogenic proteins | |
WO2000023053A3 (en) | Artificial antigen-specific cells and related methods | |
WO1998021334A3 (en) | Antibody mg1 recognizing a small subset of human hematopoietic cells | |
ATE301471T1 (en) | USE OF ANTIBODIES AGAINST CD45RO LEUKOCYTE ANTIGEN FOR IMMUNE MODULATION | |
WO1996012794A3 (en) | Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity | |
EP1003552A4 (en) | LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION | |
WO1996021734A3 (en) | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods | |
GB2261666A (en) | Multivalent anti-cytokine immunoglobulins | |
AU1971295A (en) | Humanized monoclonal antibodies against human interleukin-4 | |
CA2086131A1 (en) | Anti-human ige monoclonal antibodies | |
ATE239035T1 (en) | TUMOR REJECTION ANTIGENS PRESENTED BY HLA-B44 MOLECULES AND THEIR USES | |
DK0687300T3 (en) | LO-CD2a antibody and its uses for inhibiting T cell activation and proliferation | |
NO972522L (en) | Monoclonal antibodies with immunosuppressive activity | |
WO2001079496A3 (en) | Ligand for herpes simplex virus entry mediator and methods of use | |
DE69839943D1 (en) | PREVENT IMMUNOACTIVITY THROUGH INHIBITION OR INHIBITION OF ANTIGEN-PRESENTING CELLS | |
AU6953296A (en) | Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation | |
Orban et al. | A factor shed by lymphoblastoid cell lines of HLA-B27 positive patients with ankylosing spondylitis, specifically modifies the cells of HLA-B27 positive normal individuals. | |
EP1674575A3 (en) | Ligand for herpes simplex virus entry mediator and methods of use | |
ATE209041T1 (en) | TUMOR REJECTION ANTIGENS PRESENTED BY HLA-B44 MOLECULES AND THEIR USE | |
Gurka et al. | 107 Allergen specific T cell clones can be utilized to map allergenic epitopes for T cell activation | |
Kumar et al. | Cross reactivity and enzyme sensitivity of immunoaffinity purified Sm/RNP antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2292415 Country of ref document: CA Ref country code: CA Ref document number: 2292415 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09468029 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998939523 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999503793 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998939523 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998939523 Country of ref document: EP |